On Thursday, Regulus Therapeutics Inc (NASDAQ:RGLS)’s shares declined -4.63% to $10.50.
Regulus Therapeutics Inc (RGLS) declared that dosing has begun in a first-in-human Phase I clinical study of RG-012, a single stranded, chemically modified oligonucleotide that binds to and inhibits the function of microRNA-21 (“miR-21”). RG-012 is being developed by Regulus in a planned alliance with Genzyme, a Sanofi company, for the treatment of Alport syndrome, a life-threatening genetic kidney disease with no approved therapy. The Phase I clinical study is being conducted in the United States as a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability and pharmacokinetics of subcutaneous dosing of RG-012 in healthy volunteers.
In addition to the Phase I clinical study, Regulus is presently enrolling Alport syndrome patients in a natural history of disease study called ATHENA. With this study, which has thirteen clinical sites worldwide, Regulus aims to learn more about the changes in renal function over time in patients with Alport syndrome. Data from the ATHENA study will provide the clinical basis for the design of a Phase II study to monitor the therapeutic effect of RG-012 on the decline in renal function and time to end-stage renal disease in Alport syndrome patients. In addition, Regulus anticipates that many patients enrolled in ATHENA will be eligible to enroll in a Phase II proof-of-concept study, which Regulus anticipates to initiate under its ‘Clinical Map Initiative’ following the conclusion of the Phase I clinical study declared.
Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs for the treatment of various diseases in the United States. It uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides.
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA)’s shares gained 0.56% to $21.50.
Momenta Pharmaceuticals, Inc. (MNTA) declared that new data from studies of the Company’s novel autoimmune programs will be presented at the European League against Rheumatism Annual Congress (EULAR) 2015 Annual Meeting in Rome, Italy.
Poster Presentation:
“Targeting the Neonatal Fc Receptor (FcRn) to Mediate Autoantibody Clearance in IgG-driven Autoimmune Disease”
Date/Time: Thursday, June 11, 2015 at 12:00-1:45pm CET
- This poster summarizes the identification, characterization, and in vivo effects of Anti-FcRn (M281), a fully-human monoclonal antibody that binds the neonatal Fc receptor, thereby increasing IgG catabolism and facilitating autoantibody clearance. M281 is in preclinical development and the Company anticipates to continue to advance this product candidate with a aim of entering the clinic in late 2016.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
At the end of Thursday’s trade, VMware, Inc. (NYSE:VMW)‘s shares dipped -0.69% to $88.44.
VMware, Inc. (VMW) and Webalo, a high-productivity mobile app development platform, recently declared combined waste saving efforts on behalf of Bell Nursery, primary supplier to 178 Home Depot stores in seven states and the District of Columbia. Growing nearly 100 million plants each year, Bell utilized Webalo’s mobile supply chain and inventory solution, deployed and secured with AirWatch, to cut waste by 50 percent, saving $7 million, while also significantly decreasing its gasoline and water usage.
iPhones are issued by Bell Nursery, secured with AirWatch, and provisioned with more than 36 custom-made Webalo applications. The business-critical applications are automatically updated through the AirWatch platform, easily equipping employees with the latest versions of each application. The new system has allowed Bell to optimize its inventory across stores to provide the right mix at each location, greatly limiting the number of plants that remain unsold and are ultimately thrown out.
VMware, Inc. provides virtualization infrastructure solutions in the United States and internationally. The company’s virtualization infrastructure solutions comprise a suite of products designed to deliver a software-defined data center (SDDC), run on industry-standard desktop computers and servers, and support a range of operating system and application environments, in addition to networking and storage infrastructures. Its solutions enable organizations to aggregate multiple servers, storage infrastructure, and networks together into shared pools of capacity .
Toronto-Dominion Bank (NYSE:TD), ended its Thursday’s trading session with -1.20% loss, and closed at $43.51.
Toronto-Dominion Bank (TD) has significantly expanded its ATM footprint in Massachusetts and now offers its customers convenient access to TD banking services at 143 ATMs in select Walgreens locations.
The TD Bank branded in-store ATMs mark the company’s first expansion of ATMs within a retailer’s store network, reflecting a focus on providing convenient banking options to its customers.
This initiative represents a partnership between TD Bank and Cardtronics, the world’s largest retail ATM owner/operator and a provider of ATM services to Walgreens.
The Toronto-Dominion Bank, together with its auxiliaries, provides financial and banking services in North America and internationally. The company operates through Canadian Retail, U.S. Retail, and Wholesale Banking segments. The Canadian Retail segment offers various financial products and services, in addition to telephone, Internet, and mobile banking services to about 15 million personal and small business customers through a network of 1,165 branches and 2,867 automated banking machines in Canada.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.